The US Food and Drug Administration (FDA) has approved pimicotinib, sold as Pimjetmi, for adults with symptomatic tenosynovial giant cell tumor (TGCT) when surgery could cause more harm than good. The agency announced the approval on 10 November 2026. Pimicotinib is a kinase inhibitor made by EMD Serono, and it is taken as a once-daily pill.
What TGCT Is and Why Surgery Is Not Always the Answer
TGCT is a rare tumour that is usually not cancerous. It grows in the lining of joints, tendon sheaths and bursae, most often in the knee, hip, ankle or hand. It rarely spreads, but it can cause pain, swelling and stiffness, and over time it can damage the joint. Surgery is the main treatment, but the tumour often comes back, and repeat operations can leave patients with lasting loss of function. That gap is where drugs like pimicotinib come in.
Pimicotinib blocks colony-stimulating factor-1 receptor (CSF-1R), a protein whose signalling drives the growth of the cells that make up the tumour. It is the third CSF-1R inhibitor approved in the United States for TGCT, after pexidartinib (Turalio) and vimseltinib (Romvimza). The drug was developed by Abbisko Therapeutics and is marketed in the US by EMD Serono. China approved it in December 2025 for adults with symptomatic TGCT who were not recommended for surgery.
What the MANEUVER Trial Showed
The approval rests on MANEUVER, an international phase 3 trial. Patients with confirmed symptomatic TGCT and measurable disease, with at least one lesion of 2 cm or more, were randomly assigned to pimicotinib 50 mg or placebo once a day, in a two-to-one ratio. Surgery had to carry a risk of dysfunction or serious complications for them to enrol.
After 25 weeks, the overall response rate was 56% in the pimicotinib group, against 3.2% in the placebo group, as assessed by blinded independent central review. The median duration of response had not been reached. Of the patients who responded, 91% were still responding after six months and 77% after twelve months. The trial also met its key secondary endpoints, with significant improvements in active range of motion in the affected joint, worst pain and physical function.
Side Effects and Safety
The most common side effects, each seen in more than 20% of patients, were itching, rash, facial swelling, swelling around the eyes, fatigue, nausea, headache and swelling of the arms or legs. Common lab changes included higher levels of creatine phosphokinase, lactate dehydrogenase, liver enzymes, lipase, amylase and cholesterol. The prescribing information warns about liver damage and possible harm to an unborn baby, and about a rise in serum creatinine that does not affect kidney function. CURE Today reports that 8% of patients in the trial needed a lower dose and 2% stopped treatment because of side effects.
The recommended dose is 50 mg taken by mouth once a day, with or without food. The FDA had given the drug fast track and breakthrough therapy designations. The review ran under Project Orbis, the FDA Oncology Center of Excellence programme for concurrent review with international partners, with regulators from Australia, Canada, Israel, Switzerland and the United Kingdom taking part and the European Medicines Agency observing.
Why This Matters for Healthcare Organizations
TGCT is rare, so most clinics will see it only occasionally, but the approval still matters for referral and intake. Orthopaedic and oncology practices are the ones most likely to meet these patients, and they now have a third systemic option to discuss when surgery would cost a patient the use of a joint. That conversation usually starts with a phone call or a message from a patient who has read the news, and practices that answer those questions clearly will handle the referral better. Our look at how an AI medical receptionist handles after-hours calls covers one way clinics manage that first contact, and a patient portal that handles intake, scheduling and messages gives patients a straightforward route to ask about a new treatment and book the right appointment.
For payers and prior authorisation teams, the approval adds another high-cost oral oncology drug to the review queue, with a defined population: adults whose surgery would risk worsening function or severe morbidity. Clear documentation of that surgical risk will matter for coverage, since it is the line the approval draws.
Analysis: A Narrow Approval With a Clear Population
This is a narrow approval, and that is its strength. The FDA has not positioned pimicotinib as a general TGCT treatment. It is for the patients surgery would harm, a group with few good options and a real risk of lasting disability from repeat operations. The trial numbers support that framing: a response rate far above placebo, responses that held up over a year for most responders, and functional gains that patients would notice in daily life.
The open questions are practical ones. The drug's price has not been disclosed, and neither has the timing of commercial availability in the US. As the third drug in its class, it will also be measured against pexidartinib and vimseltinib on tolerability and ease of use, not just on response rates. For now, the approval gives clinicians and patients a new option where surgery was the only route and a poor one.
Sources and References
- U.S. Food and Drug Administration, FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor, 10 November 2026: https://www.fda.gov/drugs/cancer-approvals/fda-approves-pimicotinib-symptomatic-tenosynovial-giant-cell-tumor
- CURE Today, FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumor, 10 November 2026: https://www.curetoday.com/view/fda-approves-pimicotinib-for-tenosynovial-giant-cell-tumor
- Abbisko Therapeutics, via PR Newswire, PIMJETMI (pimicotinib) developed by Abbisko Therapeutics and licensed by Merck KGaA, Darmstadt, Germany receive U.S. FDA approval for TGCT, 10 November 2026: https://www.tradingview.com/news/prnewswire:6484bb4929404:0-pimjetmi-pimicotinib-developed-by-abbisko-therapeutics-and-licensed-by-merck-kgaa-darmstadt-germany-receive-u-s-fda-approval-for-tgct/
Reporting based on the sources above, accessed 11 November 2026. The FDA approval page was read directly, and the CURE Today and Abbisko Therapeutics reports were read directly and cross-checked against it. Med Clinic X did not conduct original reporting or interviews for this article. Corrections: contact us via https://medclinicx.com/contact